Hardt K, Vandebosch A, Sadoff J, et al. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis 2022; published online Sept 13. https://doi.org/10.1016/S1473-3099(22)00506-0—For this Article, Sarah Warren and Mihaela Pacurar should have been included in the ENSEMBLE2 investigator list. The appendix of this Article has also been corrected with an updated list. These corrections have been made to the online version as of Nov 7, 2022.
. 2022 Nov 7;23(1):e1. doi: 10.1016/S1473-3099(22)00739-3
Correction to Lancet Infect Dis 2022; published online Sept 13. https://doi.org/10.1016/S1473-3099(22)00506-0
Issue date 2023 Jan.
© 2022 Elsevier Ltd. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC9640201 PMID: 36356604
This corrects the article "Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial" in volume 22 on page 1703.